My research is aiming to study how the immune system controls viral infections in transplant patients and use this information to bolster their immunity in a test tube, providing protection against a virus the patient is unable to fight after their transplant. We are also trying to develop new strategies to use patient's own blood cells which will be grown in the laboratory and returned to the patient, resulting in a full recovery.
Treatments that target cancer causing genes called oncogenes have resulted in new treatment paradigms for cancer. We suggest that outcomes of patients with cancer will be further substantially improved by understanding how cancers can overcome resistance to these treatments that develops in many patients. To accelerate the adoption of these and other new treatments for cancer we will also develop new frameworks for clinical trials.
Utilization Of Gene-engineered T Cells For Enhancing Cancer Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$761,656.00
Summary
Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells, whilst minimizing toxicity to normal tissue.
New Strategies For Enhancing Chimeric Antigen Receptor (CAR) T Cell Therapy For Cancer
Funder
National Health and Medical Research Council
Funding Amount
$849,540.00
Summary
The role of the immune system in cancer is now recognised as highly important, highlighted by the success of immunotherapy in patients. Yet many patients fail to respond to this form of treatment due to low frequency of lymphocytes present at the tumor site. A new form of immunotherapy involving transfer of gene-modified lymphocytes is a potential way to overcome this problem. This project will explore new strategies to enhance the utility of this approach against blood and solid cancers.
This application will increase the impact of cancer immunotherapy on disease prevention and treatment, by developing new targets and novel combination immunotherapies. Outcomes will include an improved understanding of the immune reaction with cancer and more effective strategies to prevent cancer spread and safely target and eradicate a larger proportion of established and advanced malignant disease.
The human immune system comprises many different types of cells that can detect foreign molecules. My research will lead the way to understanding some of the most abundant, yet least well understood, cells within this system, collectively known as 'unconventional T cells'. This knowledge is essential to optimally and efficiently manipulate the immune system in health and disease.
Immunobilogy Of Human Herpesviruses: From Bench To Bedside
Funder
National Health and Medical Research Council
Funding Amount
$926,980.00
Summary
This Fellowship application is aiming to translate our newly emerging knowledge on immune regulation of human herpesviruses and associated diseases from bench to bedside. We are aiming develop new platform technologies which will allow us to test novel immunotherapeutic strategies to treat herpesvirus-associated diseases.
My goal is to boost the immune system against cancer to develop new therapies. I aim to do this by genetically engineering the immune system and using drugs to help strengthen white blood cells of the immune system. Tumors can actively fight immunity by producing suppressive molecules. I am seeking to identify and understand these molecules in order to block them and help the immune system fight cancer. Using this knowledge, I aim to start new clinical trials for cancer.